Download presentation
Presentation is loading. Please wait.
Published byIne Antonsen Modified over 5 years ago
1
Clopidogrel use before renal artery angioplasty with/without stent placement resulted in tertiary procedure risk reduction Albeir Y. Mousa, MD, Mike Broce, BA, John Campbell, MD, Aravinda Nanjundappa, MD, Patrick A. Stone, MD, Shadi Abu-Halimah, MD, Mohit Srivastava, MD, Mark C. Bates, MD, Ali F. AbuRahma, MD Journal of Vascular Surgery Volume 56, Issue 2, Pages (August 2012) DOI: /j.jvs Copyright © 2012 Society for Vascular Surgery Terms and Conditions
2
Fig 1 Life-table analysis between clopidogrel and acetylsalicylic acid (ASA) for target vessel revascularization (TVR). Cumulative freedom from TVR at 8 years was 93.5% for clopidogrel vs 61% for ASA (P = .51). Error bars >10% not shown. Journal of Vascular Surgery , DOI: ( /j.jvs ) Copyright © 2012 Society for Vascular Surgery Terms and Conditions
3
Fig 2 Life-table analysis between clopidogrel and acetylsalicylic acid (ASA) for in-stent restenosis (ISR). Cumulative freedom from ISR at 4 years was 27.2% for clopidogrel vs 32.9% for ASA (P = .76). Error bars >10% not shown. Journal of Vascular Surgery , DOI: ( /j.jvs ) Copyright © 2012 Society for Vascular Surgery Terms and Conditions
4
Fig 3 Life-table analysis between clopidogrel and acetylsalicylic acid (ASA) for estimated glomerular filtration rate (eGFR) < 30. Freedom for low renal function (eGFR < 30 mL/min) was more than 75% at 5 years and no group differences were found. Error bars >10% not shown. Journal of Vascular Surgery , DOI: ( /j.jvs ) Copyright © 2012 Society for Vascular Surgery Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.